---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014390"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:32:17.124859+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Q2 net loss $18M; HB-200 Phase 2 shows 43% ORR in HPV16+ head and neck cancer

## Summary
- Net loss $18.0M in Q2 2023 vs $16.4M in Q2 2022; revenue flat at $2.7M.
- Cash $136.0M at June 30, 2023, up from $113.4M at Dec 31, 2022, after $50M June offering.
- Phase 2 HB-200 + pembrolizumab: 43% ORR in CPI-naïve patients, double pembrolizumab alone; randomized trial planned H1 2024.
- R&D expenses rose $3.6M to $19.7M on higher clinical costs for HB-200, HB-300, and partnered programs.
- Exchange offer for 627,632 underwater options (exercise >$6.50) to eligible non-executive employees.

## SEC filing metadata
- accession: 0001558370-23-014390
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/0001558370-23-014390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/hook-20230810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014390
- JSON: https://secwatch.observer/filing/0001558370-23-014390.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014390.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported second quarter of 2023 results: revenue $2.7 million.
  - Period: second quarter of 2023
  - Revenue: $2.7 million
  - Result: reported results
  source text: The increase was primarily attributable to funds resulting from the follow-on financing in June 2023, partly offset by cash used in operating activities. ​ Revenue: Revenue was $2.7 million for the three months ended June 30, 2023 and for the three months ended June 30, 2022. A decrease of cost reimbursements received under the Restated Gilead Collaboration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/0001558370-23-014390-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.